Sugi Predict

Sugi Predict / Compounds / SCHEMBL4081822

SCHEMBL4081822

SCHEMBL4081822

CCNC(=O)C#Cc1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(CN(C)C)cc1)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAP2K1 Q02750 4/20 0.48
▸ CDC7 O00311 1/20 0.48
▸ PLK4 O00444 1/20 0.48
▸ AURKA O14965 1/20 0.48
▸ RPS6KA4 O75676 1/20 0.48
▸ CDKL5 O76039 1/20 0.48
▸ STK10 O94804 1/20 0.48
▸ LATS1 O95835 1/20 0.48
▸ ABL1 P00519 1/20 0.48
▸ LCK P06239 1/20 0.48
▸ FYN P06241 1/20 0.48
▸ YES1 P07947 1/20 0.48
▸ LYN P07948 1/20 0.48
▸ RET P07949 1/20 0.48
▸ HCK P08631 1/20 0.48
▸ PDGFRB P09619 1/20 0.48
▸ FGFR1 P11362 1/20 0.48
▸ SRC P12931 1/20 0.48
▸ FER P16591 1/20 0.48
▸ FECH P22830 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10326049 1.00 MAP2K1 (0.48) MAP2K1CDC7PLK4AURKARPS6KA4
SCHEMBL26907228 1.00 MAP2K1 (0.48) MAP2K1CDC7PLK4AURKARPS6KA4
SCHEMBL10325117 0.93 MAP2K1 (0.40) MAP2K1CDC7PLK4AURKARPS6KA4
SCHEMBL10293630 0.93 MAP2K1 (0.40) MAP2K1CDC7PLK4AURKARPS6KA4
SCHEMBL10325557 0.92 MAP2K1 (0.40) MAP2K1CDC7PLK4AURKARPS6KA4
SCHEMBL12237872 0.92 MAP2K1 (0.40) MAP2K1CDC7PLK4AURKARPS6KA4
SCHEMBL15427656 0.92 MAP2K1 (0.40) MAP2K1CDC7PLK4AURKARPS6KA4
SCHEMBL14353091 0.91 MAP2K1 (0.51) MAP2K1CDC7PLK4AURKARPS6KA4
SCHEMBL10293633 0.91 MAP2K1 (0.51) MAP2K1CDC7PLK4AURKARPS6KA4
SCHEMBL14353092 0.91 MAP2K1 (0.51) MAP2K1CDC7PLK4AURKARPS6KA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2014009318-A1 3-{3-[1 -(4-DIMETHYLAMINOMETHYL-PHENYLAMINO)-1 -PHENYL-METH-(Z)-YLIDENE]-2-OXO-2,3-DIHYDRO-1 H-INDOL-6-YLL-PROPYNOIC ACID ETHYLAMIDE AND ITS USE IN THE TREATMENT OF CANCER BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-01-16 — — WO claimed
US-20140018372-A1 CRYSTALLINE FORM OF A INDOLINONE DERIVATIVE AND ITS USE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-01-16 — — US claimed
EP-4662319-A2 PERSONALIZED CRISPR PROFILING FOR CANCER Integrate Bioscience LLC (US) 2025-12-17 — — EP disclosed
WO-2024168301-A2 PERSONALIZED CRISPR PROFILING FOR CANCER FUNCTION ONCOLOGY, INC. (US) 2024-08-15 — — WO disclosed
EP-2872511-A1 IMIDAZOPYRAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB Biopharma SPRL (BE) 2015-05-20 — — EP disclosed
US-8937095-B2 Anticancer compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-01-20 — — US disclosed
US-8937095-B2 Anticancer compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-01-20 — — US disclosed
US-8853420-B2 Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-10-07 — — US disclosed
US-8853420-B2 Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-10-07 — — US disclosed
US-20140194442-A1 ANTICANCER THERAPY BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-07-10 — — US disclosed
US-20140194442-A1 ANTICANCER THERAPY BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-07-10 — — US disclosed
US-20130122005-A1 ANTICANCER COMBINATION THERAPY BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-16 — — US disclosed
US-20130122005-A1 ANTICANCER COMBINATION THERAPY BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-16 — — US disclosed
WO-2013060872-A1 ANTICANCER COMBINATION THERAPY BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-02 — — WO disclosed
US-20130004481-A1 ANTICANCER THERAPY BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-03 — — US disclosed
WO-2012095505-A1 ANTICANCER THERAPY WITH DUAL AURORA KINASE / MEK INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-07-19 — — WO disclosed
EP-2471787-A1 New compounds Boehringer Ingelheim International GmbH (DE) 2012-07-04 — — EP disclosed
US-20120107304-A1 Combination therapy in treatment of oncological and fibrotic diseases BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-05-03 — — US disclosed
US-20110263565-A1 COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-10-27 — — US disclosed
US-20110263565-A1 COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-10-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140194442-A1 ANTICANCER THERAPY AURKA, AURKC, AURKB MAP2K1 8/4885CDC7 45/4885PLK4 49/4885
US-20120107304-A1 Combination therapy in treatment of oncological and fibrotic diseases AURKB, AURKC, AURKA MAP2K1 494/4885CDC7 195/4885PLK4 264/4885
US-20130004481-A1 ANTICANCER THERAPY AURKA, AURKC, AURKB MAP2K1 8/4885CDC7 45/4885PLK4 49/4885
US-20110263565-A1 COMPOUNDS MKI67, CCNA1, CCNT1 MAP2K1 4252/4885CDC7 1345/4885PLK4 2483/4885
US-20140018372-A1 CRYSTALLINE FORM OF A INDOLINONE DERIVATIVE AND ITS USE PIR, IDO1, UACA MAP2K1 2941/4885CDC7 4193/4885PLK4 321/4885
US-20130122005-A1 ANTICANCER COMBINATION THERAPY AURKA, IGF1R, AURKC MAP2K1 10/4885CDC7 125/4885PLK4 151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.